Season’s Greetings from the Infectious Diseases Clinical Research Consortium

We want to express our sincere gratitude for all your efforts during this unprecedented year. Best wishes to you and your family for a joyous and safe holiday season and a happy and healthy new year.

Profile: IDCRC Site

Alabama Vaccine Research Clinic

"It is great being involved in making a difference in the COVID pandemic. We have helped to develop two drugs so far! The ability to rapidly respond to the pandemic because of the existing infrastructure is one of the best strengths of the IDCRC."

In The News

NIH: "Baricitinib plus remdesivir shows promise for treating COVID-19"

Published December 11, 2020

The combination of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral, reduced time to recovery for people hospitalized with COVID-19, according to clinical trial results published in the New England Journal of Medicine. The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Emory Health Sciences Research Blog: "Baricitinib effectively reduces COVID-19 lung inflammation in NHP model"

Published December 10, 2020

In the race to halt the COVID-19 pandemic, researchers at Yerkes National Primate Research Center of Emory University share two important findings from their latest peer-reviewed, published study in Cell.

Rhesus monkeys are a valid animal model for COVID-19 studies because the way they experience and respond to the virus has comparable similarities to the way the virus affects humans, the researchers say. And baricitinib, an anti-inflammatory medication that is FDA-approved for rheumatoid arthritis, is remarkably effective in reducing the lung inflammation COVID-19 causes when the medication is started early after infection.

Stanwood Camano News: "Seattle Children's Hospital leads research of COVID in children"

Published December 8, 2020

At Seattle Children’s Research Institute, healthcare experts and scientists collaborate in areas like epidemiology, diagnostics, immunology, infectious disease, vaccine development and mental health, making major breakthroughs in cancer, cystic fibrosis, infectious disease, and autoimmune disorders.

The Coler Lab at Seattle Children’s Research Institute supported the Phase 1 clinical trial of an experimental coronavirus vaccine in collaboration with Kaiser Permanente Washington Health Research Institute in Seattle, part of NIAID’s Infectious Diseases Clinical Research Consortium.

Publications

View recent journal articles featuring IDCRC-supported work below:

• Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
• Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
• Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Communication Survey and Resources

Deadline: December 31, 2020

Please take a moment and complete the inaugural Infectious Diseases Clinical Research Consortium (IDCRC) communication survey. The survey will measure the success of the following year one communication goals:

• To establish a bi-directional communication funnel
• To establish an IDCRC brand
• To establish internal communication channels as outlined in the GY1 strategic communication plan

The survey is anonymous and takes approximately two minutes to complete. The results will impact IDCRC communication planning for GY2 and beyond. 

Thank you for your time and invaluable feedback. Please contact epthomp@emory.edu with any questions.

Access IDCRC communications resources on Box or visit the web-based toolkit.

IDCRC-CoVPN Studies

Event

Virtual IDCRC Annual Meeting
January 19, 2021 | 10 a.m. - 4 p.m.

IDCRC Concept Quick Stats

Please submit IDCRC news to epthomp@emory.edu for inclusion in the monthly newsletter and IDCRC.org.